MENLO PARK, Calif., Feb. 23, 2011 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, announced today that two new principal scientists, Dave Anderson, Ph.D., and William Thomsen, Ph.D., have joined its Center for Advanced Drug Research (CADRE) in Shenandoah Valley, Virginia.
Dr. Anderson will serve as principal scientist in CADRE's proteomics group. He has more than 20 years of experience applying mass spectrometry and proteomics methods to a variety of scientific problems. At SRI, he will apply those methods to set up biomarker analytics for specific disease areas and study host-pathogen interactions and pathogen drug resistance mechanisms.
Prior to joining SRI, Dr. Anderson was senior director of proteomics at Catalyst Biosciences and research fellow for proteomics and target discovery at Rigel Pharmaceuticals. Earlier, he headed the protein chemistry department at Khepri Pharmaceuticals and then at Arris Pharmaceutical following its acquisition of Khepri. In between his positions in the biotech industry, he was a research professor at the University of Oregon.
Dr. Anderson received his Ph.D. from the University of Oregon. He has authored more than 60 publications and holds 42 U.S. patents.
Dr. Thomsen will serve as principal scientist in CADRE's metabolic diseases group, where he will lead research pertaining to metabolic diseases.
He joins SRI with more than 25 years of experience in pharmaceutical drug discovery, with an emphasis on target validation, assay development, high throughput screening, and molecular pharmacology. He has experience with several classes of discovery targets, including G protein coupled receptors, within multiple therapeutic areas, including: disorders of the central nervous system; endocrine, metabolic, cardiovascular, and immunological diseases; and cancer. Most recently, he served as the director of molecular pharmacology at Arena Pharmaceuticals.
Dr. Thomsen received his Ph.D. from the University of Michigan and was a postdoctoral fellow at the University of Washington.
About SRI's Center for Advanced Drug Research (CADRE)
SRI established the Center for Advanced Drug Research (CADRE) to improve the productivity of the pharmaceutical industry, help our nation respond to biothreats, and develop life-saving treatments for rare and neglected diseases. CADRE's mission is to create new therapeutics, diagnostics, and vaccines for infectious and other diseases and for biodefense. CADRE combines and partners with SRI's well-established expertise in drug discovery, computational biology, and preclinical development with a new proteomics laboratory to develop these solutions.
About SRI's Biosciences Division
SRI's Biosciences division carries out basic research, drug discovery, and drug development, and provides contract (CRO) services. SRI has all of the resources necessary to take R&D from "Idea to IND"®—from initial discovery to the start of human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and commercial clients and partners advance many drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.
About SRI International
Silicon Valley-based SRI International, a nonprofit research and development organization, performs sponsored R&D for governments, businesses, and foundations. SRI brings its innovations to the marketplace through technology licensing, new products, and spin-off ventures. Commemorating its 65th anniversary in 2011, SRI is known for world-changing innovations in computing, health and pharmaceuticals, chemistry and materials, sensing, energy, education, national defense, and more.
SOURCE SRI International